The FDA has approved Medtronic’s Evolut transcatheter aortic valve replacement (TAVR) systems to be used in Redo TAVR procedures. This means patients who previously received a transcatheter valve and are now experiencing valve failure have a minimally invasive option instead of undergoing open-heart surgery. The expansion of this indication reflects the growing need for lifetime…